Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication

BACKGROUND: Claudication secondary to peripheral artery disease (PAD) is associated with substantial functional impairment. Phosphodiesterase (PDE) inhibitors have been shown to increase walking performance in these patients. K-134 is a selective PDE 3 inhibitor being developed as a potential treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Roger J, Connor, Jason T, Teerlink, John R, Murphy, James R, Cooper, Leslie T, Hiatt, William R, Brass, Eric P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3126735/
https://www.ncbi.nlm.nih.gov/pubmed/21612611
http://dx.doi.org/10.1186/1745-6215-12-134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3126735/
https://www.ncbi.nlm.nih.gov/pubmed/21612611
http://dx.doi.org/10.1186/1745-6215-12-134

Ejemplares similares